What Happened?
Boston, MA-based LuxCath Appointed Terry Ransbury as Chief Technology Officer
About the Company
LuxCath is the leader in using fluorescence and optics to directly view lesions during cardiac ablation procedures. The company`s breakthrough technology offers the potential for dramatic evolution in the way ablation procedures are performed by assessing tissue contact and enabling direct lesion progression monitoring. LuxCath`s patented solution aims to ensure the quality of catheter lesions at the moment they are made. LuxCath enables constant optical tissue contact assessment and provides valuable lesion formation and progression information during each ablation.
About the Person
Terry Ransbury is Chief Technology Officer at LuxCath. Previously, Terry held various senior IT leadership roles in the industry.
Info Source
Press Release
Short Profile